NASDAQ:VYGR

Voyager Therapeutics (VYGR) Stock Price, News & Analysis

Voyager Therapeutics logo
$1.56 -0.08 (-4.60%)
As of 02:20 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Voyager Therapeutics Stock (NASDAQ:VYGR)

Advanced

Key Stats

Today's Range
$1.55
▼
$1.67
50-Day Range
$1.63
▼
$3.40
52-Week Range
$1.55
▼
$5.48
Volume
557,181 shs
Average Volume
674,854 shs
Market Capitalization
$96.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Moderate Buy

Company Overview

Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases. Its work includes adeno-associated virus (AAV) gene therapies designed to deliver therapeutic genes to the nervous system.

The company’s TRACER platform is used to discover and engineer AAV capsids, including candidates intended to cross the blood-brain barrier. Voyager has researched treatments for neurodegenerative and other neurological disorders and has partnered with pharmaceutical companies to advance gene therapy programs.

Founded in 2014, Voyager is based in Lexington, Massachusetts. Its research and development activities focus on genetic medicine technologies and potential treatments for patients with serious neurological conditions.

AI Generated. May Contain Errors.

Voyager Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

VYGR MarketRank™: 
2.394356868455 of 5 stars

Voyager Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 537th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Voyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    Voyager Therapeutics has a consensus price target of $25.00, representing about 1,476.3% upside from its current price of $1.59.

  • Amount of Analyst Coverage

    Voyager Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Voyager Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Voyager Therapeutics are expected to grow in the coming year, from ($1.60) to ($1.28) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Voyager Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Voyager Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Voyager Therapeutics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.06% of the float of Voyager Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Voyager Therapeutics has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Voyager Therapeutics has recently increased by 20.30%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Voyager Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Voyager Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Voyager Therapeutics has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Voyager Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    4 people have searched for VYGR on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Voyager Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.70% of the stock of Voyager Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Voyager Therapeutics' insider trading history.
Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VYGR Stock News Headlines

Voyager Reports Third Quarter 2026 Financial and Operating Results
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
Voyager Therapeutics (VYGR) Gets a Buy from Wells Fargo
See More Headlines

VYGR Stock Analysis - Frequently Asked Questions

Voyager Therapeutics' stock was trading at $3.93 on January 1st, 2026. Since then, VYGR shares have decreased by 59.6% and is now trading at $1.5860.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) released its quarterly earnings data on Thursday, November, 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.02. The business had revenue of $612 thousand for the quarter, compared to analysts' expectations of $6.35 million. Voyager Therapeutics had a negative trailing twelve-month return on equity of 63.42% and a negative net margin of 416.32%.

Voyager Therapeutics (VYGR) raised $80 million in an initial public offering on Wednesday, November 11th 2015. The company issued 5,000,000 shares at $15.00-$17.00 per share.

Voyager Therapeutics' top institutional investors include State Street Corp (1.76%), Goldman Sachs Group Inc. (0.92%), Marshall Wace LLP (0.35%) and Empowered Funds LLC (0.12%). Insiders that own company stock include Alfred Sandrock, Robin Swartz, Nathan D Jorgensen, Todd Alfred Carter and Sandell Jacquelyn Fahey.
View institutional ownership trends
.

Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Voyager Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX) and Palantir Technologies (PLTR).

Company Calendar

Last Earnings
11/05/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VYGR
CIK
1640266
Fax
N/A
Employees
141
Year Founded
2014

Price Target and Rating

High Price Target
$25.00
Low Price Target
$25.00
Potential Upside/Downside
+1,507.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$119.72 million
Net Margins
-416.32%
Pretax Margin
-416.08%
Return on Equity
-63.42%
Return on Assets
-49.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.81
Quick Ratio
7.51

Sales & Book Value

Annual Sales
$40.37 million
Price / Sales
2.40
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.17 per share
Price / Book
0.72

Miscellaneous

Outstanding Shares
62,230,000
Free Float
54,326,000
Market Cap
$96.77 million
Optionable
Optionable
Beta
1.20

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:VYGR) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners